Dr. Maxim Frolovs laboratory uses biochemical, genetic and genome-wide approaches to gain mechanistic insights into how a cancer-relevant Retinoblastoma (Rb) pathway regulates cell proliferation and differentiation in vivo. Towards this goal, his lab is taking full advantage of the Drosophila model system, which has a streamlined version of the Rb pathway. Dr. Frolov has been working on Rb pathway since 1999, first as a postdoc with Nick Dyson laboratory at Massachusetts General Hospital Cancer Center, and for the past 10 years as a faculty member at the University of Illinois at Chicago. He has made several contributions to the field using the fly model. Among them are the finding that E2F regulation is a net result of interplay between an activator and a repressor E2Fs, genetic dissection of E2F repressor function during development, the concept of functional interaction between intronic microRNAs and the host genes they are embedded into, linking the Rb pathway to regulation of mitochondrial function.His research is focused on biochemical, genetic and genome-wide approaches to gain mechanistic insights. He also researches on Rb pathways.